AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

The impact of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, is global and unprecedented. Although remdesivir has recently been approved by the FDA to treat SARS-CoV-2 infection, no oral antiviral is available for outpatient treatment. AT-527, an orall...

Descripción completa

Detalles Bibliográficos
Autores principales: Good, Steven S., Westover, Jonna, Jung, Kie Hoon, Zhou, Xiao-Jian, Moussa, Adel, La Colla, Paolo, Collu, Gabriella, Canard, Bruno, Sommadossi, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097421/
https://www.ncbi.nlm.nih.gov/pubmed/33558299
http://dx.doi.org/10.1128/AAC.02479-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097421/
https://www.ncbi.nlm.nih.gov/pubmed/33558299
http://dx.doi.org/10.1128/AAC.02479-20

Ejemplares similares